DIGITAL THERAPEUTICS MARKET ANALYSIS

Market News

Global Digital Therapeutics Market: Key Developments

In July 2022, AmerisourceBergen planned to launch digital therapeutic (DTx) platform to facilitate access to innovative products. The platform enables doctors to easily access and order prescription and non-prescription DTx through their e-prescribing workflow and monitor patient fulfilment.

In February 2022, DynamiCare Health Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the DCH-001, a prescription-only digital therapeutic intended to treat tobacco use disorder complicating pregnancy and childbirth.

In January 2021, Epillo planned to launch its pilot project- Blockchain based Digital Therapeutic Devices (DTx) in a strategic partnership with Hydrus7 Labs, a USA based blockchain Technology Company to aggressively expand its innovation portfolio as well as broaden and accelerate product development in Europe and United States.

In June 2020, MedRhythms announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its patented digital therapeutic to treat chronic stroke walking deficits.

Global Digital Therapeutics Market: Key Companies Insights

The global digital therapeutics market is highly competitive. This is attributed to the rise in burden of chronic disease and the outbreak of COVID-19, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global digital therapeutics market are Happify, Inc., 2Morrow, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., and Fitbit, Inc. (Twine Health, Inc.).